Survodutide Once Weekly for the Treatment of Adults with Obesity
Peer-reviewed phase 3 trial; NEJM 2026, 2026 · paper · Clinical trials
A phase 3 randomized trial of once-weekly survodutide versus placebo in 725 adults with obesity without diabetes. At 76 weeks, weight fell 12.2–13.0% versus 5.4%, with gastrointestinal symptoms more common on the drug.
1 finding
Reference or label Methods says "The trial design has been published previously.23" but reference 23 is "Draft guidance for industry on developing products for weight management: availability. Fed Regist 2007"; the design paper is reference 22 (Wharton et al., "rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZE-1 and -2)").
- p. 2 Methods, Trial Design, last lines
The trial design has been published previously.23
- p. 12 Reference list, entry 23
Draft guidance for industry on developing products for weight management: availability. Fed Regist 2007
- p. 12 Reference list, entry 22
Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZE-1 and -2)
Judge's note: Page 2 image shows a superscript 23 after "published previously". The page 12 reference list shows entry 23 is the 2007 Federal Register draft guidance notice and entry 22 is the SYNCHRONIZE-1 and -2 rationale-and-design paper. A Federal Register notice cannot be the publication of this trial's design, so the call-out should be 22.
Second check: another model agreed
Report a problem with this finding
1 minor (typos and the like; most checked by the judge only)
Typo MACE is expanded as "major adverse cardiovascular events (MACE; including heart failure)" in the Methods but as "A 5-point major adverse cardiac event (5P-MACE)" in the Table 3 footnote.
- p. 2 Methods, Trial Design
adjudicated major adverse cardiovascular events (MACE; including heart failure)
- p. 9 Table 3, footnote **
A 5-point major adverse cardiac event (5P-MACE) was defined as nonfatal stroke
- p. 9 Table 3 footnote **
A 5-point major adverse cardiac event (5P-MACE)
- p. 2 Methods, Trial Design
major adverse cardiovascular events
Judge's note: Both wordings are on the page images (page 2 Methods; page 9 Table 3 footnote **). The footnote's definition includes nonfatal stroke, so "cardiovascular" is the consistent term. Both expansions are in use, the meaning is unchanged, and this is a cosmetic inconsistency.
Second check: none (judge only)